Bristol Myers Squibb’s $4.1 billion acquisition of RayzeBio aims to strengthen its cancer drug business.

Bristol Myers Squibb’s Acquisition

Bristol Myers Squibb announced its plan to acquire RayzeBio for approximately $4.1 billion, focusing on enhancing its cancer drug business. This acquisition marks the drugmaker’s second major deal in less than a week.

The post Bristol Myers Acquisition of RayzeBio for $4.1 Billion appeared first on PicaPica News.